The pharmaceutical industry constantly seeks novel and effective building blocks for drug synthesis. Among these, naturally derived compounds with established bioactivity are particularly valuable. Eupatilin (CAS 22368-21-4), a flavonoid with a rich history of medicinal plant use, has emerged as a significant pharmaceutical intermediate due to its versatile chemical structure and inherent therapeutic potential. This article explores the properties of Eupatilin that make it an attractive intermediate and discusses sourcing strategies for R&D professionals and procurement managers.

Eupatilin, formally known as 2-(3,4-Dimethoxyphenyl)-5,7-dihydroxy-6-methoxy-4H-benzopyran-4-one, is characterized by its flavonoid backbone, adorned with hydroxyl and methoxy groups. This complex structure, with the molecular formula C18H16O7, provides multiple sites for chemical modification, allowing it to be transformed into a variety of derivative compounds. Its inherent anti-inflammatory, antioxidant, and gastroprotective activities also mean that synthesized derivatives can retain or even enhance these beneficial properties, or acquire new ones relevant to specific therapeutic targets.

As a pharmaceutical intermediate, Eupatilin serves as a crucial starting material in the synthesis of more complex drug molecules. Its functional groups can undergo various chemical reactions, such as esterification, etherification, or glycosylation, to create novel chemical entities with altered pharmacokinetic and pharmacodynamic profiles. The consistent availability of high-purity Eupatilin is thus essential for the reproducible synthesis of these derivative drugs. Ensuring a purity of ≥99% is often a prerequisite for its use in pharmaceutical synthesis, as impurities can interfere with reaction pathways or contaminate the final drug product.

The application of Eupatilin as an intermediate is being explored in areas targeting inflammatory diseases, oxidative stress-related conditions, and gastrointestinal disorders. Researchers are actively investigating how structural modifications of Eupatilin can lead to more potent or targeted therapeutic agents. The demand for this compound as a reliable precursor is therefore growing within the R&D departments of pharmaceutical companies.

For organizations looking to buy Eupatilin for these purposes, sourcing from reputable manufacturers is critical. China has become a prominent global supplier of fine chemicals and pharmaceutical intermediates, including Eupatilin. Manufacturers in China often provide high-grade Eupatilin at competitive prices, owing to efficient production processes and large-scale manufacturing capabilities. When selecting a supplier, it is vital to verify their commitment to quality control, inquire about their synthesis routes, and ensure they can provide consistent batch-to-batch quality with comprehensive documentation, such as Certificates of Analysis (CoA).

Procurement managers and research scientists can leverage the availability of Eupatilin as an intermediate to accelerate their drug discovery programs. By securing a stable supply of this versatile compound, they can focus on the downstream synthesis and optimization of novel drug candidates. The chemical properties of Eupatilin, combined with its natural origin and bioactivity, position it as an increasingly important molecule in the pharmaceutical pipeline.

In conclusion, Eupatilin (CAS 22368-21-4) stands out as a valuable pharmaceutical intermediate, offering a potent scaffold for the development of new therapeutics. Its versatility in chemical modification, coupled with its inherent biological benefits, makes it a sought-after compound. By partnering with reliable manufacturers and suppliers, particularly those in China known for their expertise in fine chemical production, organizations can ensure access to the high-purity Eupatilin necessary to drive pharmaceutical innovation forward.